CN112933162A

CN112933162A - Composition with uric acid reducing effect and application thereof

Info

Publication number: CN112933162A
Application number: CN202110349697.3A
Authority: CN
Inventors: 霍虹; 贾琳; 赵晶; 范一鸣
Original assignee: Jilin Qiangsheng Bio Tech Co ltd
Current assignee: Jilin Qiangsheng Bio Tech Co ltd
Priority date: 2021-03-31
Filing date: 2021-03-31
Publication date: 2021-06-11

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to a composition with a uric acid reducing effect and application thereof. The invention takes natural adinandra nitida and natural ampelopsis grossedentata as main raw materials, and at least one of shrimp and crab shell extract, chitosan oligosaccharide, celery seed extract and black cherry extract as auxiliary materials, and the obtained composition is rich in active ingredients such as metolanin, camellin, myricetin, dihydromyricetin, apigenin and the like, and has pharmacological activities such as uric acid reduction, anti-inflammation, oxidation resistance and the like. In-vivo and in-vitro experiments show that the composition can effectively reduce the uric acid level in vivo, relieve the acute inflammatory reaction of hyperuricemia, and has the effects of dispelling wind, relieving swelling, clearing heat from throat and benefiting throat. In addition, the compound tea does not contain caffeine, does not influence sleep, has no addiction, is suitable for wide crowds, and has wide application and development prospects.

Description

Composition with uric acid reducing effect and application thereof

Technical Field

The invention relates to the technical field of traditional Chinese medicines, in particular to a composition with a uric acid reducing effect and application thereof.

Background

Uric acid is a nitrogen compound synthesized in the liver and is a main cause of gout and hyperuricemia. With the improvement of the living standard of the national people in China, the change of the eating habits and the intake of high-purine foods, the patients with hyperuricemia and gout increase year by year in China and show the trend of being younger. Hyperuricemia is a disease caused by the increase of uric acid content in blood due to purine substance metabolism disorder or uric acid excretion disorder in human body. The clinical diagnosis standard of hyperuricemia is that the serum uric acid level of men is higher than 416umol/L, and the serum uric acid level of women is 357 umol/L. When the concentration of uric acid in serum of a patient with hyperuricemia is too high, the uric acid is easy to deposit at joints to form tophus, and further causes gouty arthritis, and simultaneously can cause various metabolic syndromes such as hypertension, diabetes, kidney lesion and the like. Therefore, lowering uric acid levels in the blood to reduce gout complications is the key to treating hyperuricemia and gout.

The existing methods for treating hyperuricemia and gout mainly comprise the steps of reducing the generation of uric acid, increasing the excretion of uric acid, promoting the decomposition of uric acid, relieving the gout inflammatory reaction and the like, and corresponding medicines are developed on the basis. Such as allopurinol which is a medicament for inhibiting the generation of uric acid, benzbromarone and probenecid which are medicaments for promoting the excretion of uric acid, labyrinase which is a medicament for promoting the decomposition of uric acid, colchicine which is a medicament for relieving gouty arthritis and the like. Although the medicines can effectively improve the symptoms of gout patients and reduce the uric acid level, the toxic and side effects of the medicines can easily cause the adverse reactions of the patients, and other diseases of the patients can be caused by long-term administration, so that the life quality of the patients is influenced. Therefore, the development of a safe and efficient uric acid reducing product has important clinical value and social significance.

Disclosure of Invention

In view of the above, the present invention provides a composition with uric acid lowering effect and application thereof. The composition has remarkable effect of reducing uric acid, and is safe and free of side effects.

In order to achieve the above object, the present invention provides the following technical solutions:

the invention provides a composition, which comprises adinandra nitida, ampelopsis grossedentata and at least one of the following components:

shrimp and crab shell extract, chitosan oligosaccharide, celery seed extract and black cherry extract.

In some embodiments, the composition comprises adinandra nitida, ampelopsis grossedentata, chitosan oligosaccharide, celery seed extract, and black cherry extract.

According to research, the invention discovers that the fresh leaves of the alpine Adinandra nitida tea produced from Chinese chess mountain of Zhao Ping county in Guangxi are rich in melatonine and apigenin resource components (camellin, apigenin and the like) after being fried, have the effects of reducing urea generation, promoting uric acid decomposition, resisting inflammation and the like, can effectively reduce the uric acid level in serum, and relieve joint verification reaction. In addition, the tender shoots and tender leaves of wild Ampelopsis grossedentata produced in Hunan are rich in flavonoid components such as myricetin and dihydromyricetin, and the effective components have pharmacological activities of scavenging free radicals, resisting inflammation, protecting liver, resisting oxidation, resisting bacteria and the like, and can effectively reduce the uric acid level in blood serum and protect liver and kidney functions.

Based on the above, the invention takes natural Adinandra nitida and natural Ampelopsis grossedentata as main raw materials, and chitosan, chitosan oligosaccharide, celery seed extract and black cherry extract as auxiliary materials, and the obtained composition is rich in active ingredients such as metolanin, camellin, myricetin, dihydromyricetin, apigenin and the like, and has pharmacological activities such as uric acid reduction, anti-inflammation, oxidation resistance and the like. In-vivo and in-vitro experiments show that the composition can effectively reduce the uric acid level in vivo, relieve the acute inflammatory reaction of hyperuricemia, and simultaneously has the effects of dispelling wind, relieving swelling, clearing heat from throat and benefiting throat. In addition, the compound tea does not contain caffeine, does not influence sleep, has no addiction, is suitable for wide crowds, and has wide application and development prospects.

The specific types of adinandra nitida and ampelopsis grossedentata are not particularly limited in the present invention, and wild adinandra nitida and wild ampelopsis grossedentata are preferred. The invention has no special limit on the producing areas of the adinandra nitida and the ampelopsis grossedentata; in a specific embodiment of the invention, the Adinandra nitida tea is from high mountain Adinandra nitida tea of Chinese chess mountain in Zhaoping county in Guangxi, and the Ampelopsis grossedentata is produced in Henan Hengdong.

In some embodiments, the mass ratio of the adinandra nitida, the ampelopsis grossedentata, the chitosan oligosaccharide, the celery seed extract and the black cherry extract is (5-50): (5-75): (0.5-5): (0-5): (0.5-5): (0-5).

In some preferred embodiments, the mass ratio of the adinandra nitida, the ampelopsis grossedentata, the chitosan oligosaccharide, the celery seed extract and the black cherry extract is (25-50): 30-65): 3-5): 2-5): (2-5): (2-5). In some embodiments, the mass ratio is specifically 25:65:3:2:3:2, 40:40:5:5:2:3, 25:60:5:3:3:4, 50:30:5:5:5: 5.

In some embodiments, the shrimp and crab shell extract has a molecular weight of 10kDa to 20 kDa.

In some embodiments, the chitosan has a degree of deacetylation of greater than or equal to 75%, the chitosan oligosaccharide has a degree of deacetylation of greater than 90% and a molecular weight of less than 10 kDa.

In the invention, the preparation method of the adinandra nitida tea comprises the following steps: picking tender shoots and leaves of fresh Adinandra nitida before grain rain, parching, and air drying. In some specific embodiments, the mass ratio of the tender branches to the tender leaves in the adinandra nitida tea is 1: 1.

The preparation method of the vine tea comprises the following steps: picking tender shoot and leaf of fresh Ampelopsis Grossdentata before grain rain, parching, and air drying.

The invention also provides application of the composition in preparation of products with the effect of reducing uric acid.

The product is tea or tea beverage.

The invention also provides composite tea which is prepared from the composition. The composition can be made into tea or tea beverage according to conventional preparation process in the field. The tea or tea beverage can be in various forms such as independently packaged tea bags or tea powder, is convenient to carry and take, and is safe and environment-friendly. The tea bag of the composite tea is 3-5 g in sub-packaging specification, and 2-3 bags are drunk every day. The tea powder is packaged in 2-4 g of tea powder, and 2-3 bags of tea powder are drunk every day. The brewing temperature of the composite tea drink is 70-90 ℃ hot water, the water adding amount is 200-300 mL, the brewing time of each bag of tea drink is 20-30 minutes, and each bag can be brewed for 1-2 times.

The composition comprises Adinandra nitida, Ampelopsis grossedentata and at least one of the following components: shrimp and crab shell extract, chitosan oligosaccharide, celery seed extract and black cherry extract. Compared with the prior art, the invention has the following beneficial effects:

1. the composition is rich in effective active ingredients such as metolazin, camellin, myricetin, dihydromyricetin, apigenin and the like, and has the effects of reducing uric acid, resisting inflammation, diminishing swelling, protecting liver and kidney functions and the like;

2. the tea or tea beverage prepared by the composition does not contain caffeine, does not influence sleep, has no addiction, and has wider audience groups;

3. the tea or tea beverage prepared by the composition can be in various forms such as independently packaged tea bags or tea powder, is convenient to carry and take, and is safe and environment-friendly.

Detailed Description

The invention provides a composition with a uric acid reducing effect and application thereof. Those skilled in the art can modify the process parameters appropriately to achieve the desired results with reference to the disclosure herein. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.

The test materials adopted by the invention are all common commercial products and can be purchased in the market.

The invention is further illustrated by the following examples:

example 1

The tea drink is prepared according to the following formula:

the components are weighed according to the weight ratio, crushed and mixed evenly. Packaging under aseptic condition at a ratio of 5 g/bag. Infusing with 300mL of 90-degree boiling water for 30 min, 1 time per bag, and drinking 1 bag each day in the morning and evening.

Example 2

The tea drink is prepared according to the following formula:

the components are weighed according to the weight ratio, crushed and mixed evenly. Packaging under aseptic condition at a ratio of 4 g/bag. Soaking in 200mL boiling water of about 85 deg.C for 20 min, 2 times per bag, and drinking 1 bag each in the morning and evening.

Example 3

The tea drink is prepared according to the following formula:

weighing the components according to the weight ratio, crushing the components at low temperature under the condition of liquid nitrogen, and screening the crushed components by a 30-mesh screen for drying. Packaging at a ratio of 3 g/bag under aseptic condition. Infusing with 300mL of 90-degree boiling water for 30 min, 1 time per bag, and drinking 1 bag each day in the morning and evening.

Example 4

The tea drink is prepared according to the following formula:

the components are weighed according to the weight ratio, crushed and mixed evenly. Packaging under aseptic condition at a ratio of 5 g/bag. Soaking in 200mL boiling water of about 80 deg.C for 20 min, 2 times per bag, and drinking 1 bag each in the morning and evening.

Comparative example 1

The tea drink is prepared according to the following formula:

45 parts of wild adinandra nitida tea

55 parts of wild vine tea

Comparative example 2

The tea drink is prepared according to the following formula:

Comparative example 3

The tea drink is prepared according to the following formula:

Comparative example 4

The composition was prepared according to the following formulation:

40 parts of chitosan oligosaccharide

35 parts of celery seed extract

25 parts of black cherry extract

The components are weighed according to the weight ratio and then evenly mixed. Packaging under aseptic condition at a ratio of 5 g/bag. Soaking in 200mL boiling water of about 80 deg.C for 20 min, 2 times per bag, and drinking 1 bag each in the morning and evening.

Efficacy test

Taking the composite tea prepared in the examples 1-4 and the comparative examples 1-4, soaking and extracting the composite tea in boiling water, distilling the tea under reduced pressure to 5 g/bag, and numbering the tea in sequence as samples 1-8.

Experimental animals: taking 120 Kunming mice of 5-6 weeks old, weighing 22-26 g, and dividing the mice into 12 groups of 10 mice each according to the random grouping principle.

Grouping experiments: each group of experiments comprises a blank control group, a model group, an experiment group (samples No. 1-8) and an experiment control group (allopurinol and benzbromarone).

The administration scheme is as follows: the preparation is administered orally by intragastric administration at a dosage of 1mL/10g per day, once per day for 3 weeks. All groups were modeled except the blank control group given saline. The model group (200 mg/kg adenine, 250mg/kg ethambutol and equal volume of normal saline in the morning, administration in the afternoon), the experimental group and the experimental control group are modeled in the morning, and the administration in the afternoon (such as Liguang branch, Luzhongying, etc., the uric acid reducing effect of ampelopsis grossedentata dihydromyricetin on the mouse hyperuricemia model, the mountain agricultural biology report, 33 (4): 040-042, 2014).

Detection indexes are as follows: after 3 weeks of continuous administration, blood was collected by an eye-ball extraction method, and serum was centrifuged to determine blood Uric Acid (UA), uric acid nitrogen (BUN) and creatinine (Cr). Origin 8.0 software is adopted for data, t-test analysis is adopted between two groups, and one-factor analysis of variance is adopted between multiple groups. p <0.05 is a significant difference.

And (3) detection results:

TABLE 1 Change in serum Uric Acid (UA) levels in groups of mice 3 weeks after administration

Note: p is less than 0.05, which indicates that the results between the experimental group and the control group have significant difference with the results between the model group.

The above results indicate that the uric acid levels in mice can be significantly reduced in each administration group as compared with the hyperuricemia model group. Meanwhile, compared with an experimental control group, the compound tea of the examples 1 to 4 has an obvious effect of reducing uric acid, and the effect is obvious due to the deficient comparative examples 1 to 4. Can reduce the kidney injury caused by hyperuricemia, has better kidney protection function, reduces the adverse reaction of the medicine, has high safety, and is suitable for long-term administration. The composition has a synergistic effect among the components, and the composition is not essential.

The foregoing is only a preferred embodiment of the present invention, and it should be noted that it is obvious to those skilled in the art that various modifications and improvements can be made without departing from the principle of the present invention, and these modifications and improvements should also be considered as the protection scope of the present invention.

Claims

1. A composition comprising adinandra nitida, ampelopsis grossedentata and at least one of the following components:

2. The composition of claim 1, wherein the composition comprises Adinandra nitida, Ampelopsis grossedentata, chitosan oligosaccharide, celery seed extract, and black cherry extract.

3. The composition as claimed in claim 2, wherein the mass ratio of the adinandra nitida, the ampelopsis grossedentata, the chitosan oligosaccharide, the celery seed extract and the black cherry extract is (5-50): (5-75): (0.5-5): (0-5): (0.5-5): (0-5).

4. The composition as claimed in any one of claims 1 to 3, wherein the chitosan has a degree of deacetylation of greater than or equal to 75%, the chitosan oligosaccharide has a degree of deacetylation of greater than 90% and a molecular weight of less than 10 kDa.

5. The composition according to any one of claims 1 to 3, wherein the Adinandra nitida is prepared by a method comprising: picking tender shoots and leaves of fresh Adinandra nitida before grain rain, parching, and air drying.

6. The composition as claimed in claim 5, wherein the mass ratio of young branches to young leaves in Adinandra nitida is 1: 1.

7. A composition according to any one of claims 1 to 3, wherein the preparation method of the ampelopsis grossedentata comprises: picking tender shoot and leaf of fresh Ampelopsis Grossdentata before grain rain, parching, and air drying.

8. Use of the composition according to any one of claims 1 to 7 for the preparation of a product having uric acid lowering effect.

9. Use according to claim 8, wherein the product is a tea or tea beverage.

10. A composite tea prepared from the composition of any one of claims 1 to 7.